Editor's note: Seeking Alpha is proud to welcome James Charles Foord as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more »
Thesis Summary
This article will review the latest report by Caligan, which states that, under the right circumstances, AMAG pharmaceuticals' (AMAG) shares could trade at up to $30.
The main question investors must answer is: Can AMAG recover profitability? If the conclusion is yes, then